31% Of Participants In Stimulant Use Disorder Trials Reduced Use; 13% Achieved Abstinence

Among 2,000 adults enrolled in pharmacotherapy trials for cocaine or methamphetamine use disorder, 31.2% achieved reduced stimulant use and 13.3% achieved abstinence by the end of their respective trials, according to a recent study. All participants received cognitive behavioral therapy, and outcomes were measured across both active medication and placebo groups. Among those receiving active medication, 32.5% achieved reduced use compared with 29.3% of those receiving placebo, while abstinence rates were 13.6% and 12.7%, respectively.

The study pooled harmonized, individual-level data from 12 multisite randomized controlled trials (RCTs) sponsored by the U . . .